CytomX Therapeutics, Inc. (CTMX) — Financial ratios
Profitability, liquidity, leverage, and valuation ratios for CytomX Therapeutics, Inc., with annual and quarterly history.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| P/E Ratio | -33.83x | 2.73x | -201.06x | -1.06x | -2.40x | -4.66x |
| P/B Ratio | 5.93x | -190.73x | -2.41x | -1.23x | -605.13x | -38.88x |
| P/S Ratio | 7.71x | 0.63x | 1.13x | 1.98x | 7.44x | 4.42x |
| Profitability | ||||||
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -29.3% | 18.1% | -6.4% | -190.6% | -311.0% | -117.7% |
| Net Margin | -22.8% | 23.1% | -0.6% | -186.8% | -310.5% | -94.7% |
| EBITDA Margin | -27.5% | 19.4% | -4.3% | -186.0% | -303.8% | -113.9% |
| Liquidity | ||||||
| Current Ratio | 3.09x | 1.25x | 1.17x | 1.55x | 3.98x | 4.76x |
| Quick Ratio | 3.09x | 1.25x | 1.17x | 1.55x | 3.98x | 4.76x |
| Leverage | ||||||
| Debt/Equity | 0.04x | -20.58x | -0.29x | -0.21x | -47.22x | -3.20x |
YoY = year-over-year change. Source: FMP..